IBSA intros new dosing options for Tirosint-SOL
Americans diagnosed with hypothyroidism and their clinical providers now have access to greater dosage flexibility within levothyroxine therapy. IBSA Pharma is introducing three new dosage strengths of its Tirosint-SOL (levothyroxine sodium) oral solution to treat hypothyroidism.
The unique new dosing options – 37.5, 44 and 62.5 micrograms – are a first in the U.S. market and offer clinicians unprecedented precision and flexibility when treating patients, the company said.
The three new doses add to Tirosint-SOL’s existing 12 options and create a new industry standard of 15 strengths of levothyroxine therapy, the widest range of any therapy for hypothyroidism that is approved by the Food and Drug Administration, according to the company.
[Read more: FDA approves third indication for Lupin's generic Levoxyl]
Tirosint-SOL’s extensive dosing options provide clinicians with more choices, enabling them to adapt levothyroxine therapy to individual needs and better treat the full spectrum of hypothyroid patients. Increased dosage flexibility may also eliminate or reduce the need to change patients’ doses.
“The addition of 37.5, 44 and 62.5 microgram dosages represents a much-needed advance in levothyroxine therapy, which is the standard of care for treating hypothyroidism,” said Charles Carter, interim chair and associate professor of clinical research, Campbell University College of Pharmacy and Health Sciences.
Carter added, “Up to this time, clinicians have often instructed parents, caregivers and patients to split levothyroxine tablets to create these doses, which can result in significant dosing errors and inconvenience. Levothyroxine is a narrow therapeutic index drug with potentially deleterious clinical outcomes if administered in sub- or supratherapeutic doses. The splitting of tablets by patients can result in inconsistent levels of levothyroxine therapy, which should be a concern to clinicians and the patients they care for.”
[Read more: FDA approves Lupin's generic Synthroid tablets]
Tirosint-SOL is widely available in retail pharmacies. To help provide patients with cost-effective access to Tirosint-SOL, IBSA recently enhanced the Tirosint-SOL Copay Coupon Program. With the new program, eligible patients with commercial insurance may pay as little as $4 per one-month supply of Tirosint-SOL or $0 per three-month supply. Additional information, including money-saving options for patients without commercial insurance or with high copays or deductibles, can be found here.